6T7P image
Entry Detail
PDB ID:
6T7P
Keywords:
Title:
human plasmakallikrein protease domain in complex with active site directed inhibitor
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2019-10-22
Release Date:
2020-07-08
Method Details:
Experimental Method:
Resolution:
1.42 Å
R-Value Free:
0.18
R-Value Work:
0.15
R-Value Observed:
0.15
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Plasma kallikrein
Chain IDs:A
Chain Length:242
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation

Abstact

The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we disclose our efforts to identify potent, selective, and orally bioavailable inhibitors of FXIa. Compound 1, identified from a diverse library of internal serine protease inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromolar FXIa activity and an encouraging absorption, distribution, metabolism, and excretion (ADME) profile while being devoid of a peptidomimetic architecture. Optimization of interactions in the S1, S1β, and S1' pockets of FXIa through a combination of structure-based drug design and traditional medicinal chemistry led to the discovery of compound 23 with subnanomolar potency on FXIa, enhanced selectivity over other coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing in patients.

Legend

Protein

Chemical

Disease

Primary Citation of related structures